- Home
- Publications
- Publication Search
- Publication Details
Title
Bulevirtide and emerging drugs for the treatment of hepatitis D
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2023-10-19
DOI
10.1080/14712598.2023.2273260
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial
- (2023) Ohad Etzion et al. HEPATOLOGY
- EASL Clinical Practice Guidelines on hepatitis delta virus
- (2023) Maurizia Rossana Brunetto et al. JOURNAL OF HEPATOLOGY
- A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
- (2023) Heiner Wedemeyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—Results of A “real world” Study
- (2022) Mathias Jachs et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
- (2022) Zhenfeng Zhang et al. JOURNAL OF HEPATOLOGY
- Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies
- (2022) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study
- (2022) Alessandro Loglio et al. JOURNAL OF HEPATOLOGY
- Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta
- (2022) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Off-therapy cure of hepatitis delta after 3 years of bulevirtide monotherapy in a patient with compensated advanced cirrhosis
- (2022) Maria Paola Anolli et al. JOURNAL OF HEPATOLOGY
- Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
- (2022) Christopher Dietz et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
- (2022) Heiner Wedemeyer et al. LANCET INFECTIOUS DISEASES
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
- (2022) Man-Fung Yuen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The changing scenario of hepatitis D
- (2021) Mario Rizzetto et al. JOURNAL OF HEPATOLOGY
- In Vivo Models of HDV Infection: Is Humanizing NTCP Enough?
- (2021) Katja Giersch et al. Viruses-Basel
- Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand?
- (2021) Mario Rizzetto et al. Viruses-Basel
- Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
- (2021) Stephan Urban et al. GUT
- A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
- (2021) Cihan Yurdaydin et al. HEPATOLOGY
- The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D
- (2020) Zaigham Abbas et al. Turkish Journal of Gastroenterology
- The global prevalence of hepatitis D virus infection: systematic review and meta-analysis
- (2020) Alexander J. Stockdale et al. JOURNAL OF HEPATOLOGY
- Bulevirtide: First Approval
- (2020) Connie Kang et al. DRUGS
- Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011–2016
- (2019) Eshan U Patel et al. CLINICAL INFECTIOUS DISEASES
- Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
- (2019) Heiner Wedemeyer et al. LANCET INFECTIOUS DISEASES
- Shared and Distinct Functions of Type I and Type III Interferons
- (2019) Helen M. Lazear et al. IMMUNITY
- Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection
- (2019) Zhijiang Miao et al. JOURNAL OF INFECTIOUS DISEASES
- Economic and Healthcare Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States
- (2019) Mohamed I. Elsaid et al. HEPATOLOGY
- Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease
- (2018) Cihan Yurdaydin et al. JOURNAL OF INFECTIOUS DISEASES
- HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response
- (2016) G. A. Niro et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-term therapy of chronic delta hepatitis with peginterferon alfa
- (2014) T. Heller et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of peginterferon alpha treatment for 24 months in chronic delta hepatitis and predictors of response
- (2012) Cetin Karaca et al. ANTIVIRAL THERAPY
- Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
- (2011) Heiner Wedemeyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Special populations with hepatitis B virus infection
- (2010) Marion G. Peters HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now